Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high2,530.00 04/02/16
52 week low1,612.50 28/04/16
52 week change -285.00 (-11.37%)
4 week volume104,217 29/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Why resurgent AIM could keep rising

AIM is flying, but Andrew Hore believes it could do even better. Here, the former AIM writer of the year tells us what's dr...

Change of Directors

RNS Number: 2544U Hutchison China Meditech Limited 16 January 2017 Change of Directors London: Monday , January 16, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017 , Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of t...

Change of Directors

RNS Number: 2493U Hutchison China Meditech Limited 16 January 2017 Change of Directors London: Monday , January 16, 2017: Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017 , Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of the...

Chi-Med launches cancer studies in China

Hutchison China MediTech has initiated a phase II study of sulfatinib in second-line biliary tract cancer patients in China. ...

Fruquintinib Phase I/II Clinical Data at ASCO GI

RNS Number: 2229U Hutchison China Meditech Limited 16 January 2017 Press Release Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium London: Monday, January 16 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from the o...

Sulfatinib Phase II Study in 2nd Line BTC in China

RNS Number: 2200U Hutchison China Meditech Limited 16 January 2017 Press Release Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China London: Monday, January 16, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line ...

Fruquintinib Combination Study in 1st-Line NSCLC

RNS Number: 2196U Hutchison China Meditech Limited 16 January 2017 Press Release Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa (gefitinib) in First-Line Non-Small Cell Lung Cancer London: Monday, January 16, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase ...

Chi-Med initiates HMPL-523 clinical trials

Hutchison China MediTech Limited has initiated a phase I trial of its novel spleen tyrosine kinase (Syk) inhibitor, HMPL-52...

Equity Research (HCM)

Hutchison China MediTech Ltd.
03/08/2016
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...
edison investment research
Hutchison China MediTech Ltd.
27/05/2016
Hutchison China MediTech (Chi-Med) (HCM) is an innovative biopharma company focused on the highly lucrative global oncology and immunology markets. HCM has built a substantial pipeline of potential...
edison investment research
Hutchison China MediTech Ltd.
05/03/2015
The next 12-18 months should be the defining period as Hutchison China MediTech transitions into a fully-fledged pharmaceutical business. Solid FY14 results confirm the continuing growth at China...

Latest discussion posts More

  • Re: nice vote of confidence

    I've met Mr To on a few occasions and I'm always grateful for the answers and colour he gives to my and other Investors questions. I have no doubt he has a very good view on ...
    8-Jan-2017
    David Global
  • nice vote of confidence

    http://www.iii.co.uk/research/LSE:HCM/news/item/2208572/directors-share-dealing?context=LSE:HCM
    14-Dec-2016
    Saigon Sally
  • New Edison Research Note

    Brilliant update from Edison! http://www.edisoninvestmentresearch.com/research/report/hutchison-china-meditech642877/preview/ Great updated note - exciting times ahead
    12-Dec-2016
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'24%
NATIONAL GRID22%
BP19%
GLAXOSMITHKLINE17%
LLOYDS GRP.14%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM